Supporting Cell & Gene Therapy through Multimodal & Flexible Facilities
ISPE
OCTOBER 27, 2022
This can require special manufacturing considerations less common in well-established biopharmaceuticals, such as enzymes or monoclonal antibodies (mAbs). Cell and gene therapies (C>) have unique needs in manufacturing suites that differ from those for classic product biopharmaceuticals. These considerations include processing safety (e.g.,
Let's personalize your content